Antipyretic TRIZ Cases

Porous adsorbent storage concentrates oxygen in a lightweight disposable container, extending portable therapy time without bulky high-pressure tanks.

Sarilumab combined with DMARDs offers an IL-6R-targeted option for rheumatoid arthritis patients who do not respond to or tolerate TNF-α antagonists.

Sarilumab combined with DMARDs targets IL-6R to improve rheumatoid arthritis symptoms when TNF-α antagonists or methotrexate fall short.

A broccoli seed oil emulsion boosts topical CBD delivery into epidermis and dermis where standard cosmetic formulations penetrate poorly.

Intravenous cryopreserved mesenchymal precursor cells target high-CRP inflammatory lung disease and improve lung function within 120 days.

Targeting the TRβ pathway, these compositions reduce fibrosis and inflammation together when conventional therapies have limited efficacy and side effects.

Dual IL-18 and IL-23 blockade improves pathway coverage in IBD, aiming for higher remission rates and longer-lasting relief.

A selenite-acid topical composition treats cervical dysplasia and carcinoma while avoiding invasive surgery and dilution by body fluids.

A humanized LRRC15 antibody enables imaging and cytotoxic delivery to tumor stroma and cancer cells while avoiding broader normal tissue targeting.

An albumin-linked MMAE conjugate uses β-glucuronidase-triggered release in tumors to improve selectivity, efficacy, and dose tolerance.

Heterocyclic compounds boost Wnt pathway inhibition by promoting β-catenin degradation, helping control cancers with better pathway specificity.

Binding the extracellular region of CCR1, this antibody blocks CCL15-driven activation and cell migration for CCR1-related therapy and diagnosis.

Embedding large drug-loaded liposomes in a cross-linked hydrogel matrix cuts storage leakage and limits free drug toxicity.

A self-emulsifying soft capsule helps poorly soluble calcifediol achieve immediate oral absorption and higher bioavailability.

A buffered anti-IL-4Rα antibody formulation uses trehalose, surfactant, and pH control to limit viscosity, aggregation, and instability.

Selective antibodies target native 14-3-3 eta without cross-reacting with related isoforms, enabling more accurate arthritis diagnosis and treatment.

Phosphorous-containing phthalazinone compounds overcome weak PARP inhibition by delivering sub-100 nM enzymatic and cellular activity.

A buffered antibody formulation at pH 5.4-6.4 limits viscosity and aggregation at high concentration for stable injection.

Blocking TL1A-DR3 signaling targets Crohn's-related intestinal fibrosis and gut inflammation when anti-inflammatory therapy alone cannot prevent fibrostenosis.

Stabilizers, buffers, and surfactants keep high-concentration anti-BAFFR antibodies stable in liquid form for subcutaneous dosing.

Specific CDR-engineered anti-BDCA2 antibodies improve BDCA2 binding and inhibit CpG-A-induced IFNα and IgM secretion for autoimmune therapy.

Specific Fc-region amino acid changes improve acid stability and homogeneity while lowering Fcγ receptor binding for safer high-concentration antibodies.

High-GABA Lactococcus lactis strains reduce visceral pain within days, offering a low-cost alternative to inconsistent symptom-driven treatments.

A monoclonal anti-IL-5 antibody binds human IL-5 to lower eosinophil counts and improve treatment of severe asthma and atopic dermatitis.

An acidic stabilization junction in ADC linkers suppresses sulfhydryl exchange, reduces aggregation, and supports higher drug loading with stable PK.

CD40 agonist antibodies bypass anti-CD20 resistance by activating immune signaling, apoptosis, and ADCC against B-cell tumors.

Allosteric compounds targeting the TYK2 JH2 pseudokinase domain improve selectivity over JAK1/2/3 while reducing hematopoietic side effects.

Specific B7-H3 binding and endocytosis enable antibody, ADC, and multispecific strategies to counter tumor immune suppression.

Specific CDR sequence tuning improves α4β7 antibody targeting to maintain therapeutic effect while reducing side effects and dosing frequency.

Combining hoki roe with green-lipped mussel raises omega-3 content and delivers synergistic anti-inflammatory support for joint health.

Radiolabeled coxib conjugates target COX-2 overexpression to non-invasively localize tumors, inflammation, and infection sites.

Neutralizing TL1A with monoclonal antibodies reduces IBD inflammation and disease severity, including Crohn's disease and ulcerative colitis.

Selective TL1A-binding CDR sequences help modulate inflammatory signaling while avoiding the broader side effects seen with TNF biologics.

Controlled headspace oxygen and stabilizers keep liquid IL-17 antibodies stable by limiting oxidation, aggregation, and degradation.

By switching CAR-T recognition from HLA-related targets to L1CAM, this case improves ovarian cancer cell killing despite HLA downregulation.

Specific CDR sequence design improves IL-36R binding and delivers stronger cellular neutralization than Spesolimab to suppress inflammatory signaling.

pH-dependent anti-IL-8 antibodies inhibit IL-8 signaling to reduce inflammation, fibrosis, and adhesion without affecting fertility.

Targeted IL-11 antibodies block receptor binding to suppress fibroblast activation and ECM buildup in fibrotic disease treatment.

Heterobifunctional CyTaCs bind CCR2 and recruit exogenous antibodies to boost ADCC, improving selective depletion of pathogenic cells.

A BCMA-binding CAR improves recognition of low-antigen tumor cells, broadens B-NHL reactivity, and limits off-target effects.

Lower minocycline dosing maintains stable plasma levels to treat rosacea and acne while reducing adverse effects and discomfort.

Small IL-4R-binding nanobodies use affinity-enhancing substitutions to penetrate nasal epithelium and block inflammatory signaling without injection.